DOCSLIB.ORG

Treatment of Patients with Major Depressive Disorder

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Treatment of Patients with Major Depressive Disorder PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder Third Edition WORK GROUP ON MAJOR DEPRESSIVE DISORDER Alan J. Gelenberg, M.D., Chair Marlene P. Freeman, M.D. John C. Markowitz, M.D. Jerrold F. Rosenbaum, M.D. Michael E. Thase, M.D. Madhukar H. Trivedi, M.D. Richard S. Van Rhoads, M.D., Consultant INDEPENDENT REVIEW PANEL Victor I. Reus, M.D., Chair J. Raymond DePaulo, Jr., M.D. Jan A. Fawcett, M.D. Christopher D. Schneck, M.D. David A. Silbersweig, M.D. This practice guideline was approved in May 2010 and published in October 2010. A guideline watch, summarizing significant developments in the scientific literature since publication of this guideline, may be available at http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx. Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx. FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST The Work Group on Major Depressive Disorder reports reports receiving honoraria from lectureships for Boeh- the following potentially competing interests for the pe- ringer Ingleheim, Bristol-Myers Squibb, Cyberonics, riod from May 2005 to May 2010: Forest Pharmaceuticals, Inc., Eli Lilly and Company, and Dr. Gelenberg reports consulting for Eli Lilly and Com- Schwartz Pharma. He was involved in the creation of pany, Pfizer, Best Practice, AstraZeneca, Wyeth, Cyber- the Massachusetts General Hospital Psychiatry Academy onics, Novartis, Forest Pharmaceuticals, Inc., GlaxoSmith- (MGH-PA) and has served as a panelist in four satellite Kline, ZARS Pharma, Jazz Pharmaceuticals, Lundbeck, broadcast programs. MGH-PA programs that have indus- Takeda Pharmaceuticals North America, Inc., eResearch try support are always multi-sponsored, and curriculum Technology, Dey Pharma, PGxHealth, and Myriad Genet- development by the Academy is independent of sponsor- ics. He reports serving on speakers bureaus for Pfizer, ship; the curricula from January 2005 to March 2009 in- GlaxoSmithKline, and Wyeth. He reports receiving re- cluded sponsorship support from AstraZeneca, Bristol- search grant funding from Eli Lilly and Company, Pfizer, Myers Squibb, Cephalon, Eli Lilly and Company, Forest and GlaxoSmithKline. He reports stock ownership in Pharmaceuticals, Inc., GlaxoSmithKline, Janssen Medical Healthcare Technology Systems. Affairs LLC, Ortho-McNeil Pharmaceutical, sanofi- Dr. Freeman reports that she received research support aventis, Shire, and Wyeth. He reports equity holdings in from the Meadows Foundation, the National Institute for Compellis Pharmaceuticals, MedAvante, and Somaxon. Mental Health, the U.S. Food and Drug Administration, Dr. Thase reports that he provided scientific consulta- the Institute for Mental Health Research, Forest, Glaxo- tion to AstraZeneca, Bristol-Myers Squibb, Eli Lilly & SmithKline and Eli Lilly and Company (investigator- Company, Forest Pharmaceuticals, Inc., Gerson Lehman initiated trials), and Pronova Biocare (research materials). Group, GlaxoSmithKline, Guidepoint Global, H. Lund- She received an honorarium for case-based peer-reviewed beck A/S, MedAvante, Inc., Neuronetics, Inc., Novartis, material for AstraZeneca’s website. She reports consulting Otsuka, Ortho-McNeil Pharmaceuticals, PamLab, L.L.C., for Ther-Rx, Reliant, and Pamlab. She reports receiving Pfizer (formerly Wyeth-Ayerst Laboratories), Schering- an honorarium for speaking at an APA continuing medical Plough (formerly Organon), Shire U.S., Inc., Supernus education program that was sponsored by Forest and an Pharmaceuticals, Takeda (Lundbeck), and Transcept Phar- honorarium for speaking at a continuing medication edu- maceuticals. He was a member of the speakers bureaus for cation program sponsored by KV Pharmaceuticals. She AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Com- reports receiving an honorarium from Leerink Swann for pany, GlaxoSmithKline, Pfizer (formerly Wyeth-Ayerst participating in a focus group. Laboratories), and Schering-Plough (formerly Organon). Dr. Markowitz reports consulting for Ono Pharma- He received grant funding from Eli Lilly and Company, ceutical Co., Ltd. (2005). He reports receiving research GlaxoSmithKline, the National Institute of Mental Health, support from Forest Pharmaceuticals, Inc. (2005). He re- the Agency for Healthcare Research and Quality, and ports receiving grant support from the National Institute Sepracor, Inc. He had equity holdings in MedAvante, Inc., of Mental Health (2005–2013), the National Alliance for and received royalty income from American Psychiatric Research in Schizophrenia and Depression (2005), and Publishing, Inc., Guilford Publications, Herald House, MINT: Mental Health Initiative (2005). He reports re- Oxford University Press, and W.W. Norton and Company. ceiving royalties from American Psychiatric Publishing, Inc. His wife was employed as the group scientific director for (2005–2010), Basic Books (2005–2010), Elsevier (2005– Embryon (formerly Advogent), which does business with 2010), and Oxford University Press (2007–2010). Bristol-Myers Squibb and Pfizer/Wyeth. Dr. Rosenbaum reports attending advisory boards for Dr. Trivedi reports that he was a consultant to or on Bristol-Myers Squibb, Cephalon, Cyberonics, Forest Phar- speaker bureaus for Abbott Laboratories, Inc., Abdi Ibra- maceuticals, Inc., Eli Lilly and Company, MedAvante, him, Akzo (Organon Pharmaceuticals, Inc.), AstraZeneca, Neuronetics, Inc., Novartis, Orexigen Therapeutics, Inc., Bristol-Myers Squibb Company, Cephalon, Inc., Cyber- Organon BioSciences, Pfizer, Roche Diagnostics, Sanofi- onics, Inc., Eli Lilly and Company, Evotec, Fabre Kramer aventis, Shire, and Wyeth. He reports consulting for Aus- Pharmaceuticals, Inc., Forest Pharmaceuticals, Glaxo- pex Pharmaceuticals, Compellis Pharmaceuticals, EPIX SmithKline, Janssen Pharmaceutica Products, L.P., Johnson Pharmaceuticals, Neuronetics, Inc., Organon BioSci- & Johnson P.R.D., Meade-Johnson, Medtronic, Neuro- ences, Somaxon, and Supernus Pharmaceuticals, Inc. He netics, Otsuka Pharmaceuticals, Parke-Davis Pharmaceuti- Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx. cals, Inc., Pfizer, Inc., Sepracor, Shire Development, Solvay competing interests. The Independent Review Panel re- Pharmaceuticals, VantagePoint, and Wyeth-Ayerst Labo- viewed this guideline to assess potential biases and found ratories. He received research support from the Agency for no evidence of influence from the industry and other re- Healthcare Research and Quality, Corcept Therapeutics, lationships of the Work Group disclosed above. The Inc., Cyberonics, Inc., Merck, National Alliance for Re- Steering Committee on Practice Guidelines also reviewed search in Schizophrenia and Depression, National Insti- this guideline and found no evidence of influence from tute of Mental Health, National Institute on Drug Abuse, these relationships. The development process for this Novartis, Pharmacia & Upjohn, Predix Pharmaceuticals guideline, including the roles of the Work Group, Inde- (Epix), Solvay Pharmaceuticals, Inc., and Targacept. pendent Review Panel, Steering Committee, APA Assem- Dr. Van Rhoads reports no competing interests. bly, and APA Board of Trustees is described in “Overview The Independent Review Panel, including Drs. Reus, of Guideline Development Process” on p. 11. DePaulo, Fawcett, Schneck, and Silbersweig, report no Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx. AMERICAN PSYCHIATRIC ASSOCIATION STEERING COMMITTEE ON PRACTICE GUIDELINES John S. McIntyre, M.D., Chair (1999–2009), Consultant (2009–2010) Joel Yager, M.D., Vice-Chair (2008–2009), Chair (2009–2010) Daniel J. Anzia, M.D. Thomas J. Craig, M.D., M.P.H. Molly T. Finnerty, M.D. Bradley R. Johnson, M.D. Francis G. Lu, M.D. James E. Nininger, M.D., Vice-Chair (2009–2010) Barbara Schneidman, M.D. Paul Summergrad, M.D. Sherwyn M. Woods, M.D., Ph.D. Michael J. Vergare, M.D. M. Justin Coffey, M.D. (fellow) Kristen Ochoa, M.D. (fellow) Jeremy Wilkinson, M.D. (fellow) Sheila Hafter Gray, M.D. (liaison) STAFF Robert Kunkle, M.A., Director, Practice Guidelines Project Robert M. Plovnick, M.D., M.S., Director, Dept. of Quality Improvement and Psychiatric Services Darrel A. Regier, M.D., M.P.H., Director, Division of Research MEDICAL EDITOR Laura J. Fochtmann, M.D. Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections
Load more

Recommended publications
  • Impact of CYP2C19 Genotype on Sertraline Exposure in 1200 Scandinavian Patients
    www.nature.com/npp ARTICLE Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients Line S. Bråten 1,2, Tore Haslemo1,2, Marin M. Jukic3,4, Magnus Ingelman-Sundberg 3, Espen Molden1,5 and Marianne K. Kringen1,2 Sertraline is an (SSRI-)antidepressant metabolized by the polymorphic CYP2C19 enzyme. The aim of this study was to investigate the impact of CYP2C19 genotype on the serum concentrations of sertraline in a large patient population. Second, the proportions of patients in the various CYP2C19 genotype-defined subgroups obtaining serum concentrations outside the therapeutic range of sertraline were assessed. A total of 2190 sertraline serum concentration measurements from 1202 patients were included retrospectively from the drug monitoring database at Diakonhjemmet Hospital in Oslo. The patients were divided into CYP2C19 genotype-predicted phenotype subgroups, i.e. normal (NMs), ultra rapid (UMs), intermediate (IMs), and poor metabolisers (PMs). The differences in dose-harmonized serum concentrations of sertraline and N-desmethylsertraline-to-sertraline metabolic ratio were compared between the subgroups, with CYP2C19 NMs set as reference. The patient proportions outside the therapeutic concentration range were also compared between the subgroups with NMs defined as reference. Compared with the CYP2C19 NMs, the sertraline serum concentration was increased 1.38-fold (95% CI 1.26–1.50) and 2.68-fold (95% CI 2.16–3.31) in CYP2C19 IMs and PMs, respectively (p < 0.001), while only a marginally lower serum concentration (−10%) was observed in CYP2C19 UMs (p = 0.012). The odds ratio for having a sertraline concentration above the therapeutic reference range was 1.97 (95% CI 1.21–3.21, p = 0.064) and 8.69 (95% CI 3.88–19.19, p < 0.001) higher for IMs and PMs vs.
    [Show full text]
  • ZOLOFT® 50 Mg and 100 Mg Tablets
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME ZOLOFT® 50 mg and 100 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 50 mg tablet contains sertraline hydrochloride equivalent to 50 mg sertraline. Each 100 mg tablet contains sertraline hydrochloride equivalent to 100 mg sertraline. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM ZOLOFT 50 mg tablets: white film-coated tablets marked with the Pfizer logo on one side and “ZLT” scoreline “50” on the other. Approximate tooling dimensions are 1.03 cm x 0.42 cm x 0.36 cm. ZOLOFT 100 mg tablets: white film-coated tablets marked with the Pfizer logo on one side and “ZLT-100” or “ZLT 100” on the other. Approximate tooling dimensions are 1.31 cm x 0.52 cm x 0.44 cm. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Adults ZOLOFT is indicated for the treatment of symptoms of depression, including depression accompanied by symptoms of anxiety, in patients with or without a history of mania. Following satisfactory response, continuation with ZOLOFT therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes. ZOLOFT is indicated for the treatment of obsessive compulsive disorder (OCD). Following initial response, sertraline has been associated with sustained efficacy, safety and tolerability in up 2 years of treatment of OCD. ZOLOFT is indicated for the treatment of panic disorder, with or without agoraphobia. ZOLOFT is indicated for the treatment of post-traumatic stress disorder (PTSD). ZOLOFT is indicated for the treatment of social phobia (social anxiety disorder).
    [Show full text]
  • Paranoid – Suspicious; Argumentative; Paranoid; Continually on The
    Disorder Gathering 34, 36, 49 Answer Keys A N S W E R K E Y, Disorder Gathering 34 1. Avital Agoraphobia – 2. Ewelina Alcoholism – 3. Martyna Anorexia – 4. Clarissa Bipolar Personality Disorder –. 5. Lysette Bulimia – 6. Kev, Annabelle Co-Dependant Relationship – 7. Archer Cognitive Distortions / all-of-nothing thinking (Splitting) – 8. Josephine Cognitive Distortions / Mental Filter – 9. Mendel Cognitive Distortions / Disqualifying the Positive – 10. Melvira Cognitive Disorder / Labeling and Mislabeling – 11. Liat Cognitive Disorder / Personalization – 12. Noa Cognitive Disorder / Narcissistic Rage – 13. Regev Delusional Disorder – 14. Connor Dependant Relationship – 15. Moira Dissociative Amnesia / Psychogenic Amnesia – (*Jason Bourne character) 16. Eylam Dissociative Fugue / Psychogenic Fugue – 17. Amit Dissociative Identity Disorder / Multiple Personality Disorder – 18. Liam Echolalia – 19. Dax Factitous Disorder – 20. Lorna Neurotic Fear of the Future – 21. Ciaran Ganser Syndrome – 22. Jean-Pierre Korsakoff’s Syndrome – 23. Ivor Neurotic Paranoia – 24. Tucker Persecutory Delusions / Querulant Delusions – 25. Lewis Post-Traumatic Stress Disorder – 26. Abdul Proprioception – 27. Alisa Repressed Memories – 28. Kirk Schizophrenia – 29. Trevor Self-Victimization – 30. Jerome Shame-based Personality – 31. Aimee Stockholm Syndrome – 32. Delphine Taijin kyofusho (Japanese culture-specific syndrome) – 33. Lyndon Tourette’s Syndrome – 34. Adar Social phobias – A N S W E R K E Y, Disorder Gathering 36 Adjustment Disorder – BERKELEY Apotemnophilia
    [Show full text]
  • First Episode Psychosis an Information Guide Revised Edition
    First episode psychosis An information guide revised edition Sarah Bromley, OT Reg (Ont) Monica Choi, MD, FRCPC Sabiha Faruqui, MSc (OT) i First episode psychosis An information guide Sarah Bromley, OT Reg (Ont) Monica Choi, MD, FRCPC Sabiha Faruqui, MSc (OT) A Pan American Health Organization / World Health Organization Collaborating Centre ii Library and Archives Canada Cataloguing in Publication Bromley, Sarah, 1969-, author First episode psychosis : an information guide : a guide for people with psychosis and their families / Sarah Bromley, OT Reg (Ont), Monica Choi, MD, Sabiha Faruqui, MSc (OT). -- Revised edition. Revised edition of: First episode psychosis / Donna Czuchta, Kathryn Ryan. 1999. Includes bibliographical references. Issued in print and electronic formats. ISBN 978-1-77052-595-5 (PRINT).--ISBN 978-1-77052-596-2 (PDF).-- ISBN 978-1-77052-597-9 (HTML).--ISBN 978-1-77052-598-6 (ePUB).-- ISBN 978-1-77114-224-3 (Kindle) 1. Psychoses--Popular works. I. Choi, Monica Arrina, 1978-, author II. Faruqui, Sabiha, 1983-, author III. Centre for Addiction and Mental Health, issuing body IV. Title. RC512.B76 2015 616.89 C2015-901241-4 C2015-901242-2 Printed in Canada Copyright © 1999, 2007, 2015 Centre for Addiction and Mental Health No part of this work may be reproduced or transmitted in any form or by any means electronic or mechanical, including photocopying and recording, or by any information storage and retrieval system without written permission from the publisher—except for a brief quotation (not to exceed 200 words) in a review or professional work. This publication may be available in other formats. For information about alterna- tive formats or other CAMH publications, or to place an order, please contact Sales and Distribution: Toll-free: 1 800 661-1111 Toronto: 416 595-6059 E-mail: [email protected] Online store: http://store.camh.ca Website: www.camh.ca Disponible en français sous le titre : Le premier épisode psychotique : Guide pour les personnes atteintes de psychose et leur famille This guide was produced by CAMH Publications.
    [Show full text]
  • Psychogenic and Organic Amnesia. a Multidimensional Assessment of Clinical, Neuroradiological, Neuropsychological and Psychopathological Features
    Behavioural Neurology 18 (2007) 53–64 53 IOS Press Psychogenic and organic amnesia. A multidimensional assessment of clinical, neuroradiological, neuropsychological and psychopathological features Laura Serraa,∗, Lucia Faddaa,b, Ivana Buccionea, Carlo Caltagironea,b and Giovanni A. Carlesimoa,b aFondazione IRCCS Santa Lucia, Roma, Italy bClinica Neurologica, Universita` Tor Vergata, Roma, Italy Abstract. Psychogenic amnesia is a complex disorder characterised by a wide variety of symptoms. Consequently, in a number of cases it is difficult distinguish it from organic memory impairment. The present study reports a new case of global psychogenic amnesia compared with two patients with amnesia underlain by organic brain damage. Our aim was to identify features useful for distinguishing between psychogenic and organic forms of memory impairment. The findings show the usefulness of a multidimensional evaluation of clinical, neuroradiological, neuropsychological and psychopathological aspects, to provide convergent findings useful for differentiating the two forms of memory disorder. Keywords: Amnesia, psychogenic origin, organic origin 1. Introduction ness of the self – and a period of wandering. According to Kopelman [33], there are three main predisposing Psychogenic or dissociative amnesia (DSM-IV- factors for global psychogenic amnesia: i) a history of TR) [1] is a clinical syndrome characterised by a mem- transient, organic amnesia due to epilepsy [52], head ory disorder of nonorganic origin. Following Kopel- injury [4] or alcoholic blackouts [20]; ii) a history of man [31,33], psychogenic amnesia can either be sit- psychiatric disorders such as depressed mood, and iii) uation specific or global. Situation specific amnesia a severe precipitating stress, such as marital or emo- refers to memory loss for a particular incident or part tional discord [23], bereavement [49], financial prob- of an incident and can arise in a variety of circum- lems [23] or war [21,48].
    [Show full text]
  • Dietary Patterns Are Differentially Associated with Atypical and Melancholic Subtypes of Depression
    nutrients Article Dietary Patterns Are Differentially Associated with Atypical and Melancholic Subtypes of Depression Aurélie M. Lasserre 1,* , Marie-Pierre F. Strippoli 1 , Pedro Marques-Vidal 2 , Lana J. Williams 3, Felice N. Jacka 3, Caroline L. Vandeleur 1, Peter Vollenweider 2 and Martin Preisig 1 1 Department of Psychiatry, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland; [email protected] (M.-P.F.S.); [email protected] (C.L.V.); [email protected] (M.P.) 2 Department of Medicine, Internal Medicine, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland; [email protected] (P.M.-V.); [email protected] (P.V.) 3 Barwon Health, IMPACT—The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong 3220, Australia; [email protected] (L.J.W.); [email protected] (F.N.J.) * Correspondence: [email protected]; Tel.: +41-21-314-3552 Abstract: Diet has been associated with the risk of depression, whereas different subtypes of depres- sion have been linked with different cardiovascular risk factors (CVRFs). In this study, our aims were to (1) identify dietary patterns with exploratory factor analysis, (2) assess cross-sectional associations between dietary patterns and depression subtypes, and (3) examine the potentially mediating effect of dietary patterns in the associations between CVRFs and depression subtypes. In the first follow-up of the population-based CoLaus|PsyCoLaus study (2009–2013, 3554 participants, 45.6% men, mean age Citation: Lasserre, A.M.; Strippoli, 57.5 years), a food frequency questionnaire assessed dietary intake and a semi-structured interview M.-P.F.; Marques-Vidal, P.; Williams, allowed to characterize major depressive disorder into current or remitted atypical, melancholic, L.J.; Jacka, F.N.; Vandeleur, C.L.; and unspecified subtypes.
    [Show full text]
  • Depression and Delirium of the Older Adult Interprofessional Geriatrics
    3/1/2018 Interprofessional Geriatrics Training Program Depression and Delirium of the Older Adult HRSA GERIATRIC WORKFORCE ENHANCEMENT FUNDED PROGRAM Grant #U1QHP2870 EngageIL.com Acknowledgements Authors: Curie Lee, DNP, AGPCNP-BC, RN L. Amanda Perry, MD Editors: Valerie Gruss, PhD, APN, CNP-BC Memoona Hasnain, MD, MHPE, PhD Learning Objectives Upon completion of this module, learners will be able to: 1. Summarize the difference between delirium and depression in older adults 2. Discuss the use of standardized tools for measuring cognitive, behavioral, and/or mood changes to confirm diagnoses 3. Discuss the structured assessment method to make a differential diagnosis based on the clinical features of delirium and depression 4. Apply management principles according to pharmacologic/ nonpharmacologic strategies 5. Identify materials to educate patients and family/caregivers 1 3/1/2018 Delirium vs. Depression • Delirium and depression can coexist but are not the same diagnosis • Both have Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for diagnosis: • Delirium is the acute onset of behavioral changes and/or confusion and often has an organic cause; resolution is often as abrupt as onset • Depression can be acute or insidious in onset and can last for years; though pathology can exacerbate the depression, it is not the cause of the depression Note: Depression in the geriatric population can be confused with delirium or dementia Delirium Delirium: Definition DSM-5: Five Key Features of Delirium 1) Disturbance in attention and awareness 2) Disturbance develops over a short period of time, represents a change from baseline, and tends to fluctuate during the course of the day 3) An additional disturbance in cognition Continued on next slide..
    [Show full text]
  • Diagnostic and Management Guidelines for Mental Disorders in Primary Care
    Diagnostic and Management Guidelines for Mental Disorders in Primary Care ICD-10 Chapter V ~rimary Care Version Published on behalf of the World Health Organization by Hogrefe & Huber Publishers World Health Organization Hogrefe & Huber Publishers Seattle . Toronto· Bern· Gottingen Library of Congress Cataloging-in-Publication Data is available via the Library of Congress Marc Database under the LC Catalog Card Number 96-77394 Canadian Cataloguing in Publication Data Main entry under title: Diagnostic and management guidelines for mental disorders in primary care: ICD-lO chapter V, primary care version ISBN 0-88937-148-2 1. Mental illness - Classification. 2. Mental illness - Diagnosis. 3. Mental illness - Treatment. I. World Health Organization. 11. Title: ICD-ten chapter V, primary care version. RC454.128 1996 616.89 C96-931353-5 The correct citation for this book should be as follows: Diagnostic and Management Guidelines for Mental Disorders in Primary Care: ICD-lO Chapter V Primary Care Version. WHO/Hogrefe & Huber Publishers, Gottingen, Germany, 1996. © Copyright 1996 by World Health Organization All rights reserved. Hogrefe & Huber Publishers USA: P.O. Box 2487, Kirkland, WA 98083-2487 Phone (206) 820-1500, Fax (206) 823-8324 CANADA: 12 Bruce Park Avenue, Toronto, Ontario M4P 2S3 Phone (416) 482-6339 SWITZERLAND: Langgass-Strasse 76, CH-3000 Bern 9 Phone (031) 300-4500, Fax (031) 300-4590 GERMANY: Rohnsweg 25,0-37085 Gottingen Phone (0551) 49609-0, Fax (0551) 49609-88 No part of this book may be translated, reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without the written permission from the copyright holder.
    [Show full text]
  • Alprazolam-Induced Dose-Dependent Anorgasmia: Case Analysis Kenneth R
    BJPsych Open (2018) 4, 274–277. doi: 10.1192/bjo.2018.35 Alprazolam-induced dose-dependent anorgasmia: case analysis Kenneth R. Kaufman, Melissa Coluccio, Michelle Linke, Elizabeth Noonan, Ronke Babalola and Rehan Aziz Background increasing alprazolam to 2.5 mg total daily dose, the patient Sexual dysfunctions are associated with multiple medical and reported anorgasmia. Anorgasmia was alprazolam dose- psychiatric disorders, as well as pharmacotherapies used to dependent, as anorgasmia resolved with reduced weekend treat these disorders. Although sexual dysfunctions negatively dosing (1 mg b.i.d. Saturday/1.5 mg total daily dose Sunday). affect both quality of life and treatment adherence, patients infrequently volunteer these symptoms and clinicians do not Conclusions pose directed questions to determine their presence or severity. Sexual dysfunction is an important adverse effect negatively This issue is especially important in psychiatric patients, for influencing therapeutic outcome. This case reports alprazolam- whom most common psychotropics may cause sexual dys- induced dose-dependent anorgasmia. Clinicians/patients should functions (antidepressants, antipsychotics, anxiolytics and be aware of this adverse effect. Routine sexual histories are mood-stabilising agents). There is limited literature addressing indicated. benzodiazepines, and alprazolam in particular. Declaration of interest Aims None. To report dose-dependent alprazolam anorgasmia. Method Keywords Case analysis with PubMed literature review. Alprazolam; benzodiazepine; sexual dysfunction; anorgasmia; adverse effect; nonadherence; anxiety disorder, major depres- Results sive disorder; obsessive–compulsive disorder, attention-deficit A 30-year-old male psychiatric patient presented with new-onset hyperactivity disorder; clinical care; education. anorgasmia in the context of asymptomatic generalised anxiety disorder, social anxiety, panic disorder with agoraphobia, Copyright and usage obsessive–compulsive disorder, major depression in remission, © The Royal College of Psychiatrists 2018.
    [Show full text]
  • Relationship Between the Postoperative Delirium And
    Theory iMedPub Journals Journal of Neurology and Neuroscience 2020 www.imedpub.com Vol.11 No.5:332 ISSN 2171-6625 DOI: 10.36648/2171-6625.11.1.332 Relationship Between the Postoperative Delirium and Dementia in Elderly Surgical Patients: Alzheimer’s Disease or Vascular Dementia Relevant Study Jong Yoon Lee1*, Hae Chan Ha2, Noh June Mo2, Hong Kyung Ho2 1Department of Neurology, Seoul Chuk Hospital, Seoul, Korea. 2Department of Orthopedic Surgery, Seoul Chuk Hospital, Seoul, Korea. *Corresponding author: Jong Yoon Lee, M.D. Department of Neurology, Seoul Chuk Hospital, 8, Dongsomun-ro 47-gil Seongbuk-gu Seoul, Republic of Korea, Tel: + 82-1599-0033; E-mail: [email protected] Received date: June 13, 2020; Accepted date: August 21, 2020; Published date: August 28, 2020 Citation: Lee JY, Ha HC, Mo NJ, Ho HK (2020) Relationship Between the Postoperative Delirium and Dementia in Elderly Surgical Patients: Alzheimer’s Disease or Vascular Dementia Relevant Study. J Neurol Neurosci Vol.11 No.5: 332. gender and CRP value {HTN, 42.90% vs. 43.60%: DM, 45.50% vs. 33.30%: female, 27.2% of 63.0 vs. male 13.8% Abstract of 32.0}. Background: Delirium is common in elderly surgical Conclusion: Dementia play a key role in the predisposing patients and the etiologies of delirium are multifactorial. factor of POD in elderly patients, but found no clinical Dementia is an important risk factor for delirium. This difference between two subgroups. It is estimated that study was conducted to investigate the clinical relevance AD and VaD would share the pathophysiology, two of surgery to the dementia in Alzheimer’s disease (AD) or subtype dementia consequently makes a similar Vascular dementia (VaD).
    [Show full text]
  • Vascular Dementia Vascular Dementia
    Vascular Dementia Vascular Dementia Other Dementias This information sheet provides an overview of a type of dementia known as vascular dementia. In this information sheet you will find: • An overview of vascular dementia • Types and symptoms of vascular dementia • Risk factors that can put someone at risk of developing vascular dementia • Information on how vascular dementia is diagnosed and treated • Information on how someone living with vascular dementia can maintain their quality of life • Other useful resources What is dementia? Dementia is an overall term for a set of symptoms that is caused by disorders affecting the brain. Someone with dementia may find it difficult to remember things, find the right words, and solve problems, all of which interfere with daily activities. A person with dementia may also experience changes in mood or behaviour. As the dementia progresses, the person will have difficulties completing even basic tasks such as getting dressed and eating. Alzheimer’s disease and vascular dementia are two common types of dementia. It is very common for vascular dementia and Alzheimer’s disease to occur together. This is called “mixed dementia.” What is vascular dementia?1 Vascular dementia is a type of dementia caused by damage to the brain from lack of blood flow or from bleeding in the brain. For our brain to function properly, it needs a constant supply of blood through a network of blood vessels called the brain vascular system. When the blood vessels are blocked, or when they bleed, oxygen and nutrients are prevented from reaching cells in the brain. As a result, the affected cells can die.
    [Show full text]
  • Depression and Anxiety: a Review
    DEPRESSION AND ANXIETY: A REVIEW Clifton Titcomb, MD OTR Medical Consultant Medical Director Hannover Life Reassurance Company of America Denver, CO [email protected] epression and anxiety are common problems Executive Summary This article reviews the in the population and are frequently encoun- overall spectrum of depressive and anxiety disor- tered in the underwriting environment. What D ders including major depressive disorder, chronic makes these conditions diffi cult to evaluate is the wide depression, minor depression, dysthymia and the range of fi ndings associated with the conditions and variety of anxiety disorders, with some special at- the signifi cant number of comorbid factors that come tention to post-traumatic stress disorder (PTSD). into play in assessing the mortality risk associated It includes a review of the epidemiology and risk with them. Thus, more than with many other medical factors for each condition. Some of the rating conditions, there is a true “art” to evaluating the risk scales that can be used to assess the severity of associated with anxiety and depression. Underwriters depression are discussed. The various forms of really need to understand and synthesize all of the therapy for depression are reviewed, including key elements contributing to outcomes and develop the overall therapeutic philosophy, rationale a composite picture for each individual to adequately for the choice of different medications, the usual assess the mortality risk. duration of treatment, causes for resistance to therapy, and the alternative approaches that The Spectrum of Depression may be employed in those situations where re- Depression represents a spectrum from dysthymia to sistance occurs.
    [Show full text]